Terumo Completes Acquisition of WuXi Biologics Drug Product Plant in Leverkusen, Germany

Terumo Corporation has successfully finalized its acquisition of a Drug Product Plant and associated Quality Control Laboratory from WuXi Biologics in Leverkusen, Germany, with the transaction officially closing on September 30, 2025. This strategic move is set to bolster Terumo’s position in the Contract Development and Manufacturing Organization (CDMO) sector.

The acquisition not only expands Terumo’s integrated service offerings but also enhances its capabilities to support biopharmaceutical companies in the launch of effective injectable treatment options. By leveraging its expertise and advanced technologies, Terumo aims to accelerate innovation and deliver increased value to pharmaceutical customers and their patients.

The Leverkusen facility, compliant with current Good Manufacturing Practice (cGMP) standards, is equipped with state-of-the-art technology and staffed by professionals with extensive production knowledge. This strategic asset will allow Terumo to provide fill & finish services for vials and polymer prefillable syringes, addressing the rising demand for CDMO services in Europe and the United States, particularly as the biopharmaceutical market continues to expand rapidly.

Noritsugu Fujita, Division President of Terumo’s Pharmaceutical Solutions Division, emphasized that this enhanced European footprint will empower biopharmaceutical companies to bring effective treatments for chronic diseases to market more efficiently. Currently, Terumo operates three CDMO production facilities in Japan and is committed to expanding its production capacity in line with the growth of its CDMO business.

With this acquisition, Terumo not only strengthens its global operations but also positions itself as a key player in the development of pharmaceutical primary containers and combination products that integrate pharmaceuticals and medical devices. The company’s focus on global CDMO expansion remains a crucial aspect of its growth strategy, offering integrated solutions that streamline the development process for pharmaceutical manufacturers.